Warning: The NCBI web site requires JavaScript to function. more...
P53 autoantibodies in 1006 patients followed up for breast cancer.
Metcalfe S, Wheeler TK, Picken S, Negus S, Jo Milner A.
Breast Cancer Res. 2000;2(6):438-43. Epub 2000 Aug 21.
Related citations
The relationship between serum p53 autoantibodies and characteristics of human breast cancer.
Mudenda B, Green JA, Green B, Jenkins JR, Robertson L, Tarunina M, Leinster SJ.
Br J Cancer. 1994 Jun;69(6):1115-9.
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M; German Breast Group.
Breast Cancer Res. 2008;10(2):R30. Epub 2008 Apr 1.
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
BMC Cancer. 2007 Apr 12;7:63.
p53 autoantibodies can be indicative of the development of breast cancer relapse.
Regele S, Vogl FD, Kohler T, Kreienberg R, Runnebaum IB.
Anticancer Res. 2003 Jan-Feb;23(1B):761-4.
Detection of p53 auto-antibodies in the sera of breast cancer patients with a new recurrence using an ELISA assay. Does a correlation with the recurrence free interval exist?
Regidor PA, Regidor M, Callies R, Schindler AE.
Eur J Gynaecol Oncol. 1996;17(3):192-9.
Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast.
Regele S, Kohlberger P, Vogl FD, Böhm W, Kreienberg R, Runnebaum IB.
Br J Cancer. 1999 Oct;81(4):702-4.
The significance of p53 autoantibodies in the serum of patients with breast cancer.
Willsher PC, Pinder SE, Robertson L, Nicholson RI, Ellis IO, Bell JA, Blamey RW, Green JA, Robertson JF.
Anticancer Res. 1996 Mar-Apr;16(2):927-30.
Serum p53 auto-antibodies: incidence in familial breast cancer.
Green JA, Mudenda B, Jenkins J, Leinster SJ, Tarunina M, Green B, Robertson L.
Eur J Cancer. 1994;30A(5):580-4.
Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study.
Lenner P, Wiklund F, Emdin SO, Arnerlöv C, Eklund C, Hallmans G, Zentgraf H, Dillner J.
Br J Cancer. 1999 Feb;79(5-6):927-32.
Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L, Canney P, Dyczka J, Rutgers E, Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J, Therasse P, Paridaens R; European Organisation for Research and Treatment of Cancer Breast Group; Scottish Breast Cancer Trials Group.
Eur J Cancer. 2007 Jan;43(2):331-40. Epub 2006 Nov 28.
Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia.
Singletary SE, Atkinson EN, Hoque A, Sneige N, Sahin AA, Fritsche HA Jr, Lotan R, Lu T, Hittelman WN, Bevers TB, Stelling CB, Lippman SM.
Clin Cancer Res. 2002 Sep;8(9):2835-42.
Serum p53 antibodies in correlation to other biological parameters of breast cancer.
Sangrajrang S, Arpornwirat W, Cheirsilpa A, Thisuphakorn P, Kalalak A, Sornprom A, Soussi T.
Cancer Detect Prev. 2003;27(3):182-6.
Anti-p53 autoantibody in colorectal cancer: prognostic significance in long-term follow-up.
Suppiah A, Alabi A, Madden L, Hartley JE, Monson JR, Greenman J.
Int J Colorectal Dis. 2008 Jun;23(6):595-600. Epub 2008 Mar 11.
Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53.
Beenken SW, Grizzle WE, Crowe DR, Conner MG, Weiss HL, Sellers MT, Krontiras H, Urist MM, Bland KI.
Ann Surg. 2001 May;233(5):630-8.
Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA.
Yie SM, Luo B, Ye NY, Xie K, Ye SR.
Clin Exp Metastasis. 2006;23(5-6):279-89. Epub 2006 Nov 3.
Autoantibodies in breast cancer: their use as an aid to early diagnosis.
Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, Barnes A, Robertson J.
Ann Oncol. 2007 May;18(5):868-73. Epub 2007 Mar 7.
Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer.
Anderson KS, Ramachandran N, Wong J, Raphael JV, Hainsworth E, Demirkan G, Cramer D, Aronzon D, Hodi FS, Harris L, Logvinenko T, LaBaer J.
J Proteome Res. 2008 Apr;7(4):1490-9. Epub 2008 Feb 27.
Absence of p53 autoantibodies in a significant proportion of breast cancer patients.
Vojtesek B, Kovarik J, Dolezalova H, Nenutil R, Havlis P, Brentani RR, Lane DP.
Br J Cancer. 1995 Jun;71(6):1253-6.
A systematic overview of chemotherapy effects in breast cancer.
Bergh J, Jönsson PE, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.
Acta Oncol. 2001;40(2-3):253-81. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on